About NsGene
NsGene is a company based in Ballerup (Denmark) founded in 1999. It operates as a B2B. NsGene has raised $5.14 million across 3 funding rounds from investors including European Union, Neurosearch and Danmarks Eksport- og Investeringsfond. NsGene operates in a competitive market with competitors including Impel NeuroPharma, CraniUS, Cognos Therapeutics, Palyon Medical and Bionxt, among others.
- Headquarter Ballerup, Denmark
- SectorsHealthcare
- Website nsgene.dk
- Legal Name Nsgene A/S
- Total Equity Funding$5.14M (USD)
in 3 rounds
- Latest Funding Round$303.63K (USD), Grant
Feb 2017
- InvestorsEuropean Union
& 4 more
Funding Insights of NsGene
NsGene has successfully raised a total of $5.14M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $303.63 thousand completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.14M
- Total Rounds 3
- Last Round Grant — $303,627
- First Round $5.14M
(May 2005)
- Investors Count 5
All 3 funding rounds of NsGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $303,627 | Grant | – | – | |
| Nov 2013 | $545,000 | Grant | – | – | – |
| May 2005 | $5.14M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in NsGene
NsGene has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Neurosearch and Danmarks Eksport- og Investeringsfond.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provision of financing, loans, equity, and insurance for Danish export and investment activities. | – | vf.dk | - | |
- | – | dankap.dk | - | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Develops pharmaceutical agents targeting ion channels and central nervous system disorders. | 1989 | neurosearch.com | Ballerup, Denmark | |
Administers holiday and hardship funds for Danish employees and employers. | 1980 | ld.dk | Hojbjerg, Denmark |
Investor details for NsGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NsGene
3 dated milestones of NsGene across 18 years, from founding to its latest funding, stage changes and deals.
- Founded NsGene is founded.
- Funding First funding round of $5.1M.
- Funding Latest funding round, Grant, of $304K.
Competitors of NsGene
NsGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, CraniUS, Cognos Therapeutics, Palyon Medical and Bionxt, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| craniustherapeutics.com | 2021 | Baltimore, United States | $20.5M | – | Drug delivery systems for brain diseases and disorders are developed. | |
| cognosthx.com | 2015 | Los Angeles, United States | $5.75M | 13 | Cognos Therapeutics is focused on innovative neurological and oncological treatments. | |
| palyonmedical.com | 2004 | New York, United States | $24M | – | Develops implantable drug delivery systems for central nervous system disorders. | |
| bionxt.com | 2018 | Vancouver, Canada | – | 49 | Drug formulations and delivery systems for diseases are developed. | |
| cordancemedical.com | 2018 | Mountain View, United States | – | – | Non-invasive ultrasound device for blood-brain barrier is developed. | |
| passport-tech.com | 2019 | San Diego, United States | – | – | Transdermal drug delivery systems are developed using microporation technology. | |
| biotinc.com | 2017 | San Jose, United States | – | – | Delivery systems for cell therapies are developed and targeted. | |
| neurochase.com | 2020 | Cardiff, United Kingdom | – | 4 | Provides targeted CNS therapy delivery and consultancy for pharma and biotech industries. |
Detailed competitors of NsGene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to NsGene
10 companies that operate in the same segment as NsGene (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NsGene
NsGene was founded in 1999 and raised its 1st funding round 6 years after it was founded.
NsGene is headquartered in Ballerup, Denmark.
NsGene is a funded company, having raised a total of $5.14M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5.14M, raised on May 2005.
NsGene, founded in 1999 in Ballerup, Denmark, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and cns drug delivery. Specializes in drug delivery systems and therapeutics for central nervous system diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
NsGene's top competitors include Impel NeuroPharma, CraniUS and Cognos Therapeutics.
NsGene has 5 investors. Key investors include European Union, Neurosearch, Danmarks Eksport- og Investeringsfond, DKA Capital, and LD Fonde.
NsGene operates through Nsgene A/S.